yesterdays high was 0.085, expecting HOD at 0.095 today.
will allow the Company to operate well into 2014, where we expect to begin generating revenue through LymPro commercialization and bring MANF closer to first-in-man human clinical studies
Will be interesting to see if we get news today regarding LYMPRO from Gerald at the conference.
Market Data 
Markets 
AI
